Delisle M J
Département de Médicine nucléaire, Institut Jean Godinot, Reims.
Presse Med. 1988 Jun 25;17(25):1301-4.
A change in ideas concerning the use of radioactive iodine in the treatment of hyperthyroidism has revived interest in this therapy. We report the results of an enquiry conducted in all French nuclear medicine units regarding their activity in 1985 and compare these results with those of a similar enquiry conducted simultaneously in Belgium. The amount of radioactive iodine administered in France was one-half of that administered in Belgium. Regional differences were quite marked in France, probably due to different schools of thought. Diffuse hyperthyroidism accounted for two-thirds of the indications. Most patients received one single dose. The primary objective was a return to euthyroidism, but one third of the units accepted the risk of hypothyroidism. Synthetic antithyroid drugs were often used as adjuvants. In one-half of the units, the radioactive dose administered to each patient was calculated from the effective period of the radioelement and from the thyroid mass. In 1 out of 3 units the patients were hospitalized in a controlled area for a mean period of 3 days. French doctors generally respected the 40-year age limit and systematically excluded children and teenagers. Long-term follow-up was carried out in only 50 per cent of the units.
关于放射性碘在治疗甲状腺功能亢进症中应用的观念转变,重新唤起了人们对这种疗法的兴趣。我们报告了一项针对所有法国核医学单位1985年业务活动进行的调查结果,并将这些结果与同时在比利时进行的类似调查结果进行比较。法国使用的放射性碘剂量是比利时的一半。在法国,地区差异相当明显,这可能是由于不同的思想流派所致。弥漫性甲状腺功能亢进症占适应症的三分之二。大多数患者接受单次剂量。主要目标是恢复甲状腺功能正常,但三分之一的单位接受了甲状腺功能减退的风险。合成抗甲状腺药物常作为辅助药物使用。在一半的单位中,给予每位患者的放射性剂量是根据放射性元素的有效期和甲状腺质量计算得出的。三分之一的单位中,患者在控制区域住院平均3天。法国医生通常遵守40岁的年龄限制,并系统地排除儿童和青少年。只有50%的单位进行了长期随访。